P072 Activity and clinical outcomes of New Agents (NAs) administered as third or fourth line after the failure of docetaxel (DOC) and another NA in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. Final results of an Italian multicentre retrospective study
| Autor: | Caffo, O., De Giorgi, U., Fratino, L., Alesini, D., Basso, U., Facchini, G., Gasparro, D., Ortega, C., Tucci, M., Verderame, F., Campadelli, E., Re, G. Lo, Procopio, G., Sabbatini, R., Donini, M., Morelli, F., Sartori, D., Zucali, P., Conteduca, V., Maines, F., Galligioni, E. |
|---|---|
| Zdroj: | In European Urology Supplements November 2014 13(5):135-136 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect